OncoTalks: Oncology Insights at Your Fingertips

NSCLC METex 14 Skipping

In this OncoTalks episode, Dr. David Waterhouse and Dr. Paul Conkling discuss NSCLC and the groundbreaking developments in treating patients with METex 14 skipping mutations. We review the science behind these targeted therapies, their clinical applications, and the impact on patient outcomes. This episode offers vital information to help navigate treatment options and empower patients. Don’t miss this engaging discussion on a crucial topic in oncology, filled with expert insights!

Exploring Second Line Treatments for Extensive Stage Small Cell Lung Cancer

In this episode, Dr. David Waterhouse and Dr. Paul Conkling discuss the evolving landscape of second line treatments for extensive stage small cell lung cancer. They review the latest research, promising therapies, and the impact of these treatments on patient quality of life. This episode offers vital information to help navigate treatment options and empower patients. Don’t miss this engaging discussion on a crucial topic in oncology, filled with expert insights!

Managing Ocular Side Effects in ELAHERE Treatment

In this episode, Kristen Lamoreau, OD, delves into the critical role eye care professionals play in managing ocular adverse events for patients undergoing treatment with ELAHERE, the first and only antibody-drug conjugate targeting folate receptor alpha (FRα). As a groundbreaking treatment for certain types of resistant ovarian cancer, ELAHERE is associated with ocular toxicities, necessitating a collaborative approach between eye care providers and oncology teams.
 

Management & Proactive Care in EGFR+ mNSCLC Treatment

Welcome to episode three of three. In this episode, Dr. Alex Spira and Dr. Josh Zabari, both experts in thoracic oncology, delve into the common side effects experienced by patients undergoing treatment for locally Advanced or Metastatic EGFR+ Non-Small Cell Lung Cancer (NSCLC). They discuss the importance of early identification and management of these side effects to optimize patient care and prevent treatment discontinuation.
Listen in to review strategies for addressing dermatologic and gastrointestinal toxicities, the role of multidisciplinary teams, and the significance of continuous communication with patients and caregivers. This educational opportunity is brought to you by Johnson & Johnson. 
 

Resistance Mechanisms in EGFR+ mNSCLC

Welcome to episode two of three where Dr. John Hamack from MD Anderson Cancer Center and Dr. Millie Doss from Stanford University discuss the latest advancements and ongoing challenges in treating locally Advanced or Metastatic EGFR+ Non-Small Cell Lung Cancer (NSCLC). 
Explore the unmet needs in first-line therapy, the variety of resistance mechanisms, and the evolving landscape of treatment strategies.  This educational opportunity is brought to you by Johnson & Johnson. 
 

Unmet Needs in EGFR+ mNSCLC

Welcome to episode one of three, where we dive deep into the challenges and advancements in managing locally Advanced or Metastatic EGFR+ Non-Small-Cell Lung Cancer (NSCLC). This educational opportunity is brought to you by Johnson & Johnson. 
Join Dr. Mark Socinski, Executive Medical Director of the Advent Health Cancer Institute, and Dr. Dave Waterhouse from Oncology Hematology Care in Cincinnati, Ohio, as they discuss the importance of biomarker testing, the evolution of treatment strategies, and the impact of effective first-line therapies on patient outcomes.